Please login to the form below

Not currently logged in
Email:
Password:

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  
 FDA building

The US FDA has approved Bristol-Myers Squibb's Evotaz in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Evotaz combines BMS' Reyataz (atazanavir) with Gilead Science's boosting agency cobicistat as part of a once-daily pill to be taken over a 48-week course.

The treatment is the outcome of an agreement made between BMS and Gilead in 2011, when they agreed to develop and market a fixed-dose combination HIV treatment

Murdo Gordon, head of worldwide markets at BMS, commented: “Evotaz increases the possibility of providing HIV suppression by combining reduced pill burden with a low rate of virologic failure and zero protease inhibitor mutations.”

Cobicistat is already a crucial part of several HIV treatments, including Rezolsta/Prezcobix, which pairs the drug with Janssen's Prezista (darunavir), and Gilead's own combination therapy Stribild.

Reyataz is also a successful monotherapy treatment for HIV managing worldwide revenues of more than $1bn for the first nine months of 2014.

BMS is responsible for the manufacturing and sale of the cobicistat-boosted eyataz product and will pay Gilead royalties on sales.

 

Article by
Kirstie Pickering

2nd February 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics